When you are looking for a company that’s taking on an important mission at scale, it’s hard to think of one more impactful than American Gene Technologies (AGT). That’s because AGT is leveraging the power of gene and cell therapy to reduce human suffering and extend quality of life for individuals with serious diseases. AGT is developing and commercializing genetic medicines targeting major diseases, including HIV/AIDS, Phenylketonuria (PKU) and Hepatocellular carcinoma (liver cancer, or HCC). The company’s drug candidates have achieved initial proof of concept in preclinical studies and have potential to deliver cost-effective therapies that are better targeted and more potent with fewer side effects. While AGT’s gene therapies will treat symptomatic diseases, the medicines are intended to provide durable cures that extend the length and improve the quality of patients’ lives.

But it’s not just what the people at AGT are solving, it’s how they’re doing it. The AGT team is creating solutions for patients across a spectrum of infectious diseases, cancers, and autosomal disorders in collaboration with leading medical researchers from around the globe. AGT partners with pharmaceutical and biotech firms on indication and platform-specific opportunities to enhance their proprietary platform to expedite drug development.

AGT is in the process of finding people who are passionate about this mission and who remain focused on the goal throughout the drug development journey. These characteristics are critical to success and minimize delays in getting effective therapies to patients. Think about becoming part of a team that works to positively change lives and end suffering from human diseases.